Infectious complications after transrectal MRI-targeted and systematic prostate biopsy

Inari Kalalahti1,2,5 · Kaisa Huotari3 · Andrew. M. Erickson2,4 · Anssi Petas1,2 · Hanna Vasarainen1,2 · Antti Rannikko1,2

Received: 2 May 2022 / Accepted: 9 July 2022 / Published online: 5 August 2022 © The Author(s) 2022

Abstract

Purpose To compare infectious complications after transrectal systematic prostate biopsy (SB) and magnetic resonance imaging (MRI)-targeted biopsy (TB) in a large retrospective cohort to assess whether one technique is superior to the other regarding infectious complications.

Methods A total of 4497 patients underwent 5288 biopsies, 2875 (54%) SB and 2413 (46%) MRI-TB only. On average, 12 SB cores and 3.7 MRI-TB cores were taken per biopsy session during the study period. Infection-related complications within 30 days were compared. The primary endpoint was a positive urine culture. Secondary endpoints were positive blood cultures, urine tests with elevated leukocytes ≥ 100 E6/L and elevated C-reactive protein (CRP) ≥ 100 mg/L. Chi-square test was used to compare the cohorts.

Results Positive urine cultures were found in 77 (2.7%) after SB and in 42 (1.7%) after MRI-TB (p = 0.022). In total, 46 (0.9%) blood culture positive infections were found, 23 (0.9%) occurred after SB and 23 (1.0%) after MRI-TB, (p = 0.848). Urine tests with elevated leukocytes ≥ 100 E6/L were found in 111 (3.9%) after SB and in 61 (2.5%) after MRI-TB (p = 0.006). Elevated CRP ≥ 100 mg/L was found in 122 (4.2%) after SB and in 72 (3.0%) after MRI-TB (p = 0.015). Blood cultures were drawn more often after SB than after MRI-TB, but the difference was not statistically significant. However, urine cultures and CRP were taken more often after SB than MRI-TB.

Conclusion Blood culture positive infections were equally rare after SB and MRI-TB. However, all other infectious complications were more common after SB than MRI-TB.

Keywords Infection · Complication · Targeted · Transrectal · Perineal · Prostate biopsy

Introduction

Prostate biopsy (PB) is a key step in the diagnosis and follow-up of prostate cancer (PC) and is the only way to obtain histopathological diagnosis in the absence of operative procedures such as radical prostatectomy or transurethral resection of the prostate. PB is also performed repeatedly during active surveillance. Although PB is generally considered a safe procedure, it can be associated with complications. A recent systematic review found bleeding to be the most common complication [1]. Infections after PB vary from mild lower urinary tract infections to febrile bacteremia and urosepsis. Infection rates after transrectal biopsy range from 0.1 to 7.0% and sepsis rates range from 0.3 to 3% [2, 3]. Hospitalization rates due to infections after PB are rising globally [4, 5]. Transperineal biopsy has been shown to significantly reduce infections compared to transrectal biopsy [6], but because of the need for anesthesia transrectal biopsy is still used in many clinics. Antibiotic prophylaxis is recommended as standard of care for all patients but antibiotic overuse has led to increasing antibiotic resistance [7], and as a consequence the most common microbe to cause infection after PB is fluoroquinolone-resistant Escherichia coli [8, 9].
Magnetic resonance imaging (MRI) and MRI-targeted biopsy (MRI-TB) improves the detection of PC compared to SB [10, 11]. Although smaller studies have reported on infections complications after MRI-TB, to our knowledge no studies have done so in a larger setting. In this study, we analyzed infectious complications after transrectal SB and MRI-TB occurring within 30 days of the procedure. In this setting, we aimed to establish if one technique is superior to the other regarding infections.

Patients and methods

All patients who had undergone PB at Helsinki University Hospital between January 1, 2015 and September 5, 2019 were retrospectively entered into the study. Infection-related laboratory data within 30 days of the biopsy were obtained from the hospital laboratory database and compared between SB and MRI-TB. The obtained test results were: positive urine cultures, positive blood cultures, urine tests with elevated leukocytes ≥ 100 E6/L and elevated C-reactive protein (CRP) ≥ 100 mg/L. We also compared the frequency of tests taken as this reflects the suspicion of infection: blood cultures drawn (even if negative), urine cultures taken (even if negative) and CRP tests taken (even if not elevated).

The final dataset included 4497 patients and 5288 biopsy procedures. Out of these, 2875 (54%) were SB and 2413 (46%) were MRI-TB only (i.e., no concomitant SB taken). All biopsies were transrectal biopsies. In MRI-TB, no concomitant SB is routinely taken at our center. SB patients always received 12 cores, while MRI-TB patients received 3.7 cores on average. Most MRI-TB patients had only one suspicious lesion on MRI: 83% had one lesion, 15% had two lesions, and 2% had three lesions. MRI-TB was performed using a software-guided system (UroNav; Philips Healthcare, Best, The Netherlands). The medical charts of all patients with blood culture positive infections were reviewed to verify the source of infection. Three cases were identified as not being related to biopsy (a diverticulitis, an erysipelas and one infection related to catheterization) and were excluded from the analyses.

Antibiotic prophylaxis at our institution at the time of the study was ciprofloxacin 750 mg p.o. 1 h before biopsy. If the patient has traveled abroad within three months, fosfomycin trometamol 3 g p.o. was used instead of ciprofloxacin.

Chi-square test was used to compare the cohorts. Data were analyzed using R Statistical Software (version 4.0.5, Foundation for Statistical Computing, Vienna, Austria). The cutoff level for statistical significance was set at \( p < 0.05 \) for all tests.

Results

Blood culture positive infections were rare in our data. In the entire cohort, 46 (0.9%) blood culture positive infections were identified. Out of these, 23 (0.9%) occurred after SB and 23 (1.0%) after MRI-TB \((p = 0.848)\). Most infections occurred or were suspected within the first few days after biopsy (Figs. 1 and 2).

For all of the other endpoints, there was a statistically significant difference in favor of MRI-TB (Table 1). Positive urine cultures were found in 77 (2.7%) after SB and in 42 (1.7%) after MRI-TB \((p = 0.022)\). Urine tests with elevated leukocytes ≥ 100 E6/L were found in 111 (3.9%) after SB and in 61 (2.5%) after TB \((p = 0.006)\). CRP ≥ 100 mg/L was found in 122 (4.2%) after SB and in 72 (3.0%) after TB \((p = 0.015)\).

For the tests taken, CRP and urine cultures were taken significantly more often after SB than MRI-TB. Blood cultures were drawn more often after SB than after MRI-TB, but the difference was not statistically significant (Table 1).

Discussion

Signs and symptoms of infectious complications were more common after SB than MRI-TB. We did not find a statistically significant difference between the cohorts in blood culture positive septic infections, the most feared form of infectious complication. This was expected and reflects the low number of events, i.e., lack of statistical power for this. As all other infectious complications, surrogates, were more common after SB, it suggests that a difference in bacteremic infections may exist as well. In order for us to have detected a difference of 0.8% vs 1.2% with the power of 0.80, we would have needed almost 8000 patients per group. Interestingly, a randomized trial was recently launched in the USA to compare transrectal biopsies to transperineal biopsies for a “change in infection adverse events” with a planned enrollment of 1302 patients [12].

In transrectal biopsy, the needle punctures the bowel wall and may spread bacteria on its route to the prostate. In MRI-TB, 3 to 5 cores are usually taken per lesion. Since most patients only have one lesion, the number of cores needed is much lower in MRI-TB than in SB where 12 cores are taken per patient. In our study, typical signs of urinary tract infections, positive urinary cultures, elevated CRP and leucocytes in urine were all more common after SB than MRI-TB. The CRP test is not specific to urogenital infections and it is possible that some observed CRP
elevations were due to other infections and may not be biopsy-related. However, the timeline of the CRP elevation coincided with the biopsy. If a patient is experiencing symptoms of urinary tract infections after biopsy urine cultures and CRP tests are common investigations. Both urine cultures and CRP tests were taken more often after SB. This supports the assumption that infectious complications are more common after SB.

The risk of bleeding and pain after PB has been associated to an increasing number of biopsy cores [13, 14].
A similar relationship has not clearly been seen for infections. A recent systematic review did not find an association between the number of biopsy cores and infectious complications [15]. However, a multicenter RCT comparing different biopsy techniques found that an increase in the cores taken led to an increase in infectious complications, although the difference was not statistically significant [16]. Our study demonstrates a relationship between the number of cores taken and increased infectious complications.

Several factors that may influence the risk of complications after PB have been studied. These include prior antibiotic treatment, foreign travel, comorbidities, the number of biopsy cores taken, number of injections for periprostatic nerve block, the type and size of biopsy needle and rectal enema before biopsy [15]. The risk of infection is lower in transperineal biopsy. In the transperineal approach, the biopsy needle avoids the rectal mucosa that is heavily contaminated by bacteria and cannot be fully disinfected. Because of this advantage, transperineal biopsy is now the recommended standard of care by the European Association of Urology guidelines [17]. The use of the transperineal technique is still limited because it typically requires anesthesia although transperineal biopsy in local anesthesia currently gaining more attention. In transperineal biopsy, the infection rate can be as low as 0.1% [6]. The sepsis rate in our study was 0.9%, but this could be lowered by additional methods such as povidone–iodine preparation, which was initiated at our center after the study period.

A limitation of this study is the retrospective design. This limitation is partially balanced by our large dataset. As blood culture positive infections occur at a very low rate, a large dataset is essential in studying them. Despite our large dataset, our study was underpowered for post-biopsy septic infections that in our center occur at a relatively low rate.

Based on our results, we advocate a biopsy strategy where less cores are taken and to omit SB when MRI-TB is applicable. Our data suggest a correlation between the number of biopsy cores and increased likelihood of infection. Transperineal is also a sensible method to further reduce prostate biopsy-related infections.

### Table 1 Infectious complications in the cohorts

|                          | Systematic biopsy | MRI-targeted biopsy | p value |
|--------------------------|-------------------|---------------------|---------|
| Blood culture positive infection, N (%) | 23 (0.9)          | 23 (1.0)            | 0.848   |
| Positive urine culture, N (%)      | 77 (3)            | 42 (2)              | 0.022   |
| Urine test with elevated leukocytes ≥ 100 E6/L, N (%) | 111 (4)           | 61 (3)              | 0.006   |
| CRP ≥ 100 mg/L, N (%)            | 122 (4)           | 72 (3)              | 0.015   |
| Blood cultures drawn, N (%)      | 106 (4)           | 85 (4)              | 0.750   |
| Urine cultures taken, N (%)      | 328 (11)          | 206 (9)             | < 0.001 |
| CRP taken, N (%)                | 403 (14)          | 246 (10)            | < 0.001 |

*CRP* C-reactive protein, *MRI* magnetic resonance imaging

---

**Author contribution** IK was involved in project development, data collection and management, manuscript writing and editing. KH and AR helped in project development and manuscript editing. AME contributed to data analysis and manuscript editing. AP was involved in data collection and manuscript editing. HV helped in manuscript editing.

**Funding** Open Access funding provided by University of Helsinki including Helsinki University Central Hospital. This research was supported by grants from K. Albin Johansson foundation in 2020 and from the Juhani Aho Foundation for Medical Research in 2021 to L.K. This work was also supported in part by Competitive State Research Funding (VTR) administered by Helsinki University Hospital (HUS) (to Prof. Rannikko), Finnish Cancer Organizations (to Prof. Rannikko) and Jane and Aatos Erkko Foundation (to Prof. Rannikko).

**Declarations**

**Conflict of interest** I Kalalhti reports personal grants from K. Albin Johansson foundation in 2020 and from the Juhani Aho Foundation for Medical Research in 2021. A Rannikko reports grants from State Research Funding (VTR), Finnish Cancer Organizations and Jane and Aatos Erkko Foundation. K Huotari, AM Erickson, A Petas and H Vasarainen have nothing to declare.

**Research involving human participants and/or animals** The use of registry data was approved by the Helsinki University Hospital (HUS) institutional board (HUS/333/2019).

**Informed consent** Due to the retrospective study design, informed consent was waived, and the participants were not contacted.

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
References

1. Borghesi M, Ahmed H, Nam R et al (2017) Complications after systematic, random, and image-guided prostate biopsy. Eur Urol 71(3):353–365
2. Liss MA, Ehdai B, Loeb S et al (2017) An update of the American Urological Association white paper on the prevention and treatment of the more common complications related to prostate biopsy. J Urol 198(2):329–334
3. Loeb S, Vellekoop A, Ahmed HU et al (2013) Systematic review of complications of prostate biopsy. Eur Urol 64(6):876–892
4. Nam RK, Sasaki R, Lee Y et al (2013) Increasing hospital admission rates for urological complications after transrectal ultrasound guided prostate biopsy. J Urol 189(1):S12–S17
5. Lundström KJ, Drevin L, Carlsson S et al (2014) Nationwide population based study of infections after transrectal ultrasound guided prostate biopsy. J Urol 192(4):1116–1122
6. Bennett HY, Roberts MJ, Doi SA, Gardiner RA (2016) The global burden of major infectious complications following prostate biopsy. Epidemiol Infect 144(8):1784–1791
7. Zowawi HM, Harris PN, Roberts MJ et al (2015) The emerging threat of multidrug-resistant Gram-negative bacteria in urology. Nat Rev Urol 12(10):570–584
8. Liss MA, Johnson JR, Porter SB et al (2015) Clinical and microbiological determinants of infection after transrectal prostate biopsy. Clin Infect Dis 60(7):979–987
9. Kalalah I, Huotari K, Lahdensuo K et al (2018) Rectal *E. coli* above ciprofloxacin ECOFF associate with infectious complications following prostate biopsy. Eur J Clin Microbiol Infect Dis 37(6):1055–1060
10. Kasivisvanathan V, Rannikko AS, Borghi M et al (2018) MRI-targeted or standard biopsy for prostate-cancer diagnosis. N Engl J Med 378(19):1767–1777
11. Wegelin O, Exterkate L, van der Leest M et al (2019) The FUTURE trial: a multicenter randomized controlled trial on target prostate biopsy techniques based on magnetic resonance imaging in the diagnosis of prostate cancer in patients with prior negative biopsies. Eur Urol 75(4):582–590
12. National Library of Medicine (U.S.) (2021) ClinivalTrials.gov, transperineal vs. transrectal MRI-targeted prostate biopsy. Identifier NCT04185876. https://clinicaltrials.gov/ct2/show/NCT04185876
13. Chowdhry R, Abbas A, Idriz S, Hoy A, Rutherford EE, Smart JM (2012) Should warfarin or aspirin be stopped prior to prostate biopsy? An analysis of bleeding complications related to increasing sample number regimes. Clin Radiol 67(12):64
14. Eineluoto JT, Jarvinen P, Kilpelainen T et al (2018) Patient experience of systematic versus fusion prostate biopsies. Eur Urol Oncol 1(3):202–207
15. Pradere B, Veeratterapillay R, Dimitropoulos K et al (2021) Non-antibiotic strategies for the prevention of infectious complications following prostate biopsy: a systematic review and meta-analysis. J Urol 205(3):653–663
16. Wegelin O, Exterkate L, van der Leest M et al (2019) Complications and adverse events of three magnetic resonance imaging-based target biopsy techniques in the diagnosis of prostate cancer among men with prior negative biopsies: results from the FUTURE Trial, a multicentre randomised controlled trial. Eur Urol Oncol 2(6):617–624
17. Mottet N, van den Bergh RCN, Briers E et al (2021) EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer-2020 update. Part 1: screening, diagnosis, and local treatment with curative intent. Eur Urol 79(2):243–262

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.